Meeting
2020 Genitourinary Cancers Symposium
Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.
Authors
Ronan Flippot
Dana-Farber Cancer Institute, Boston, MA
Ronan Flippot , Ziad Bakouny , Xiao X. Wei , David A. Braun , Bradley Alexander McGregor , John A. Steinharter , Lauren Christine Harshman , Ulka N. Vaishampayan , Mariano Severgnini , David F. McDermott , F. Stephen Hodi , Gwo-Shu Mary Lee , Eliezer Mendel Van Allen , Sabina Signoretti , Toni K. Choueiri , Rana R. McKay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT02724878
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 740)
Abstract #
740
Poster Bd #
J16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Immune landscape of patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated with atezolizumab plus bevacizumab.
First Author: Renee Maria Saliby
Poster
2023 ASCO Genitourinary Cancers Symposium
Exploration of immunosuppressive features of the tumor microenvironment within hepatic and non-hepatic tumors of urothelial origin.
First Author: Jacqueline T Brown
Poster
2019 ASCO Annual Meeting
Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.
First Author: Ronan Flippot
Poster
2024 ASCO Genitourinary Cancers Symposium
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
First Author: Mathilde Cancel